RA

•Erythropoietin/CD131 Receptor Agonist: Cibinetide is an EPO-like peptide that can selectively activate the innate repair receptor (IRR) composed of the erythropoietin receptor and the β – common receptor. This activation can initiate anti-inflammatory and tissue repair pathways, providing potential therapeutic benefits without the hematopoietic side effects associated with EPO.
• Anti-inflammatory and Tissue Repair: By activating IRR, Cibinetide can reduce inflammatory responses and promote tissue repair, including neuroprotection and improved vascular health.
• Neuroprotection: Cibinetide has demonstrated protective effects on nerve cells in animal models, reducing apoptosis of nerve cells and promoting nerve regeneration.
• Neuropeptide Y (NPY) Receptor Antagonism: Cibinetide competitively binds to the NPY Y₁ receptor, blocking the appetite – stimulating and energy metabolism – regulating effects mediated by NPY, reducing food intake and promoting fat breakdown.
• Metabolic Regulation: Cibinetide can enhance insulin sensitivity and improve glucose tolerance, with potential applications in the treatment of obesity and type 2 diabetes.